



RECEIVED

JUL 13 2001

TECH CENTER 1600/2900

PATENT
ST00010

1645
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BERENBAUM ET AL. EXAMINER: NOT ASSIGNED

SERIAL NO. : 09/808,388 ART UNIT : 1645

FILED : MARCH 14, 2001

FOR : INFLAMMATION INDUCIBLE HYBRID PROMOTERS,
VECTORS COMPRISING THEM AND THEIR USES
THEREOF

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on July 9, 2001.

William C. Coppola, Reg. No. 41,686
(Name of Registered Representative)

Ahmeda Danielle
(Signature and Date)

INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. 1.56, 1.97 AND 1.98

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication, or other information referred

to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b)(3), because it is being filed before the mailing of a first office action on the merits. However, if it is subsequently determined that this information disclosure statement has been filed after the mailing of a first office action, the Commissioner is hereby authorized to charge any fee due under 37 C.F.R. 1.17(P), or credit any overpayment, to account No. 18-1982.

Applicants concurrently submit herewith a PTO-1449 form and copies of references listed therein.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'William C. Coppola', is written over a horizontal line.

William C. Coppola
Attorney for Applicants
Registration No. 41,686

Aventis Pharmaceuticals Products Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854